This white paper provides a plain-language guide to the European Union's Tissue and Cells Directives — Directive 2004/23/EC and its two implementing directives, 2006/17/EC and 2006/86/EC. It explains the scope and key requirements of these directives, how they have been transposed into UK law, the practical obligations they place on tissue establishments, and how electronic traceability systems can help laboratories and tissue banks meet their compliance obligations efficiently and with confidence.
The EU Tissue and Cells Directive (Directive 2004/23/EC) was adopted by the European Parliament and the Council on 31 March 2004. Its purpose was to establish a harmonised framework across all EU Member States for setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage, and distribution of human tissues and cells intended for human application.
Prior to the Directive, the regulation of human tissue varied significantly between Member States. Some countries had comprehensive national legislation; others had minimal oversight. The Directive was intended to create a common minimum standard, ensuring that all tissue and cell products applied to patients within the EU — whether sourced domestically or imported — met consistent quality and safety requirements.
The Directive was supplemented by two implementing directives: Commission Directive 2006/17/EC, which laid down technical requirements regarding the selection, evaluation, and testing of tissue and cell donors; and Commission Directive 2006/86/EC, which specified requirements for traceability, notification of serious adverse reactions and events, and certain technical standards for coding, processing, preservation, storage, and distribution.
In the United Kingdom, these directives were transposed into national law through the Human Tissue (Quality and Safety for Human Application) Regulations 2007, which amended the Human Tissue Act 2004 framework. The Human Tissue Authority (HTA) was designated as the UK's competent authority responsible for implementing and enforcing these regulations. Following the UK's departure from the European Union, the regulations have been retained in UK law (with minor amendments) and the HTA continues to enforce them.
The Directive applies to "tissue establishments" — any organisation, body, or institution that carries out any activity involving the procurement, testing, processing, preservation, storage, or distribution of human tissues and cells intended for human application. "Human application" means the use of tissues or cells on or in a human recipient, including extracorporeal applications (such as the use of cells in assisted reproduction technologies).
In practical terms, this includes NHS tissue banks, hospital tissue services, eye banks, cord blood banks, reproductive medicine centres, skin banks, musculoskeletal tissue processors, and any other establishment that handles human tissue for therapeutic purposes. Research laboratories that handle tissue solely for research purposes (and not for human application) are not directly covered by the Directive's quality and safety requirements, although they remain subject to the Human Tissue Act's provisions on consent, governance, and traceability.
It is important to note that the Directive does not apply to blood and blood products (which are covered by a separate directive), organs for transplantation (covered by Directive 2010/53/EU), or tissues and cells used as autologous grafts within the same surgical procedure.
The Directive and its implementing measures impose a wide range of obligations on tissue establishments. The most significant from a traceability and quality perspective are outlined below.
Authorisation and licensing. Every tissue establishment must be authorised (licensed) by the competent authority in its Member State. In the UK, this means holding an HTA licence. The authorisation process includes an assessment of the establishment's premises, equipment, staff qualifications, quality management system, and traceability procedures.
Quality management system. Tissue establishments must implement and maintain a quality management system that covers, at a minimum: standard operating procedures (SOPs) for all critical processes; personnel training and competency assessment; equipment qualification and maintenance; premises and environmental monitoring; documentation control; traceability; handling of non-conformances, complaints, and recalls; and internal audit. The quality system must be documented and subject to regular review.
Donor selection and testing. Commission Directive 2006/17/EC specifies the criteria for donor selection and the mandatory laboratory tests that must be performed on donors of tissues and cells intended for human application. These include tests for HIV, Hepatitis B and C, and syphilis, with additional tests required depending on the donor's medical and behavioural history. The results of these tests must be recorded and linked to the donated tissue throughout its lifecycle.
Traceability. Article 8 of the parent Directive requires Member States to ensure that all tissues and cells procured, processed, stored, or distributed on their territory can be traced from the donor to the recipient and vice versa. Commission Directive 2006/86/EC elaborates on this requirement, specifying that traceability must be achieved through accurate identification procedures, record-keeping systems, and an appropriate labelling system. Records must be kept for a minimum of 30 years after clinical use.
The Single European Code (SEC). Commission Directive (EU) 2015/565 introduced the Single European Code — a mandatory coding system for tissues and cells distributed for human application. The SEC consists of a donation identification sequence (identifying the tissue establishment and the unique donation number) and a product identification sequence (identifying the product type using the EU Tissue Establishment Compendium and the EU Coding Platform). The SEC is designed to facilitate cross-border traceability and ensure that any tissue product distributed within the EU can be traced back to its establishment and donation of origin.
Serious adverse events and reactions (SAER). Tissue establishments must have systems in place to record, investigate, and report any serious adverse event (an untoward occurrence that may affect the quality and safety of tissues and cells) or serious adverse reaction (an unintended response in a donor or recipient that is associated with the procurement or clinical application of tissues and cells). These must be reported to the competent authority within defined timeframes, and the establishment must be able to perform a rapid traceability lookback to identify all affected donors, products, and recipients.
Import and export. The Directive includes provisions governing the import of tissues and cells from third countries (non-EU states). Importing tissue establishments must ensure that the imported material meets equivalent quality and safety standards, and must maintain traceability records that link the imported tissue to its source.
For tissue establishment staff — quality managers, laboratory scientists, technicians, and administrators — the Directive translates into a set of tangible daily obligations.
Every tissue sample must be uniquely identified and labelled from the moment of procurement. Every movement — from one room to another, from one freezer to another, from storage to processing, from quarantine to release — must be documented with the identity of the person responsible and the date and time. Every processing step must be recorded against a validated SOP. Every test result must be linked to the correct donor and the correct tissue product. Every distribution must include documentation that allows the recipient organisation (and ultimately the recipient patient) to be identified and linked back to the original donation.
These obligations generate a substantial documentation burden. For establishments handling large numbers of samples across multiple storage locations, maintaining this level of documentation manually — using paper logbooks, printed forms, or spreadsheets — is not only labour-intensive but also inherently risky. The volume of data, the number of linkages that must be maintained, and the requirement for rapid retrieval in the event of a SAER all point towards the need for an electronic system.
A purpose-built tissue traceability system can address the Directive's requirements systematically and efficiently.
Unique identification and coding. The system assigns unique identifiers to every donation, product, and storage location automatically, eliminating the risk of duplication or transcription errors. For establishments required to use the Single European Code, the system can generate SEC-compliant labels that include both the donation identification sequence and the product identification sequence.
Full lifecycle traceability. The system records every stage in the tissue lifecycle — procurement, receipt, testing, processing, storage, quarantine, release, distribution, and disposal — as structured, linked data. At any point, a user can query the system to retrieve the complete history of any sample, from donor to current status, in seconds.
Automated audit trails. Every action in the system is automatically logged with the user identity, date, time, and the nature of the change. This audit trail is immutable — it cannot be edited or deleted by end users — providing the tamper-evident record keeping that the Directive and the HTA require.
SAER lookback capability. When a serious adverse event or reaction is reported, the system allows the establishment to perform a rapid lookback — tracing from a single donor to all derived products and their recipients, or from a single recipient back to the donor and all other recipients who received material from the same donation. This capability, which might take hours or days with paper records, can be completed in minutes with an electronic system.
Quality system integration. Many electronic traceability platforms integrate with or support the broader quality management system — managing SOPs, tracking staff training and competency, recording equipment calibration, and capturing non-conformance reports and CAPAs. This integration means that all quality and traceability data resides in a single, auditable system rather than being scattered across paper files and separate databases.
Reporting and export. The system can generate reports for regulatory submission, management review, and internal audit on demand — in standardised formats that meet the competent authority's expectations. This is particularly valuable when responding to HTA inspection requests or preparing annual activity reports.
Following the UK's departure from the European Union on 31 January 2020 and the end of the transition period on 31 December 2020, the EU Tissue and Cells Directives ceased to have direct effect in the UK. However, the UK Government retained the transposed regulations (the Human Tissue (Quality and Safety for Human Application) Regulations 2007, as amended) in domestic law. The HTA continues to regulate tissue establishments against these standards, and the practical obligations on establishments remain largely unchanged.
For establishments that import tissue from EU Member States, or export tissue to them, there are additional considerations around import agreements, third-country recognition, and documentation requirements. The HTA has published guidance for establishments navigating these arrangements. An electronic traceability system that supports import and export documentation can simplify this process considerably.
It is also worth noting that the European Commission published a proposal in July 2022 to revise the EU's legislation on blood, tissues, and cells — potentially replacing the existing directives with a new regulation. While this would not directly affect UK law, establishments that import from or export to the EU should be aware that the regulatory landscape may continue to evolve.
The EU Tissue and Cells Directives established a comprehensive framework for the quality and safety of human tissues and cells intended for human application. For tissue establishments in the UK, these requirements — transposed into domestic law and enforced by the HTA — are a day-to-day reality. They demand robust traceability, comprehensive documentation, a functioning quality management system, and the ability to respond rapidly to adverse events.
While the obligations are significant, they are also manageable — particularly for establishments that invest in purpose-built electronic traceability systems. Such systems do not eliminate the need for good processes and competent staff, but they provide the infrastructure that makes comprehensive traceability achievable, sustainable, and — when the inspector arrives — demonstrable.
